Evidence map›Paper›PMID 41760910›Full record

ArticlePediatric research2026

Short-time intensive phototherapy of hyperbilirubinemic neonates: efficacy, bilirubin rebound and risk factors for rebound.

Mette Line Donneborg, Kristina Thorsteinsson, Niels H Bruun, Finn Ebbesen

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07694635 (Predictors of Rebound Hyperbilirubinemia After Phototherapy in Neonates), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07694635 not yet recruitingnot on this map

Predictors of Rebound Hyperbilirubinemia After Phototherapy in Neonates

Typeobservational_patient_registrySponsorHaseki Training and Research HospitalRan2026 to 2026Enrolled300ConditionsNeonatal Hyperbilirubinemia, Rebound Hyperbilirubinemia
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mette Line DonneborgDepartment of Pediatrics- and Adolescents medicine, North Denmark Regional Hospital, Hjoerring, Denmark. mld@rn.dk.
Kristina ThorsteinssonDepartment of Pediatrics and Adolescents Medicine, Aalborg University Hospital, Aalborg, Denmark.
Niels H BruunResearch Data and Biostatistics, Aalborg University Hospital, Aalborg, Denmark.
Finn EbbesenDepartment of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAim: To determine efficacy, frequency of bilirubin rebound, and risk factors for rebound for late preterm or term neonates with hyperbilirubinemia receiving short intensive phototherapy.

methodsThis is a prospective clinical single-arm quality assurance study. The neonates received 12 h intensive, double phototherapy (65 + 39 µW/cm

resultsIn total, 103 neonates were included in the study. The efficacy expressed by the decrease in total serum bilirubin (TSB) was 36%, and 14 (13.6%) of the 103 neonates developed rebound. The risk of rebound increased with decreasing gestational- and postnatal age, also difference between TSB at cessation of therapy and phototherapy threshold. Maturity was predominant. Mixed feeding was associated with increasing rebound frequency. The rebound frequencies in the previous studies were 14.3% and 16.7%, respectively. These frequences were not significantly different from the present rebound frequency.

conclusionShort, intensive double phototherapy was efficient and rebound hyperbilirubinemia did not seem to increase compared to conventional overhead treatments. Shorter treatment reduces parent-neonate separation, which may benefit parent-neonate bonding and breastfeeding. IMPACT: The predominant risk factors of bilirubin rebound after phototherapy (12 h) were gestational age and postnatal age, expressing the maturity. When planning post-phototherapy follow-up, risk factors should be considered, especially the maturity. Neonates with gestational age <37 weeks and postnatal age ≤72 h should routinely receive 24 h treatment. The rebound frequency did not seem to increase compared to conventional single-directed treatments.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.